Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.95
(3.15%)
SEK 2.95
(3.15%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -41.34 Million | -32.95 Million | -30.16 Million | -22.99 Million | -26.56 Million | -13.36 Million |
| Net Income | -44.61 Million | -41.47 Million | -26.94 Million | -23.01 Million | -22.87 Million | -15.49 Million |
| Depreciation & Amortization | 677 Thousand | 3.53 Million | 1.38 Million | 322 Thousand | 153.34 Thousand | 7468.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -284 Thousand | 5.53 Million | -3.8 Million | 136 Thousand | -2.91 Million | 2.97 Million |
| Other non-cash items | 4.5 Million | -560 Thousand | -802 Thousand | -445 Thousand | -922.78 Thousand | -846.84 Thousand |
| Investing Cash Flow | - | - | -1.82 Million | -3.83 Million | -4.17 Million | -7.17 Million |
| Investments in PPE | - | - | -1.82 Million | -3.83 Million | -4.17 Million | -7.17 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -1.76 Million | -2.32 Million | -2.82 Million | -6.72 Million |
| Financing Cash Flow | 41.86 Million | 25.34 Million | 39.5 Million | 16.96 Million | 28.91 Million | 36.79 Million |
| Debt repayment | -1.26 Million | -2.08 Million | -9.92 Million | -1.8 Million | -14.95 Million | -1.7 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 43.12 Million | 9 Million | 43.21 Million | 13.05 Million | 13.95 Million | 25.99 Million |
| Other Financing Activities | 43.12 Million | 18.43 Million | 6.21 Million | 5.71 Million | 13.96 Million | 12.5 Million |
| Accounts receivables | 2.25 Million | 4.19 Million | -2.59 Million | -2.96 Million | -1.56 Million | 86.99 Thousand |
| Accounts payables | -1.08 Million | 2.93 Million | -1.68 Million | 4.81 Million | -1.35 Million | 2.88 Million |
| Inventory | -1.45 Million | -1.59 Million | 479 Thousand | -1.71 Million | - | - |
| Other working capital | -1.08 Million | 2.93 Million | -1.68 Million | 4.81 Million | -1.35 Million | 2.88 Million |
| Cash at beginning of period | 4.13 Million | 12.2 Million | 4.73 Million | 14.6 Million | 16.43 Million | 164.76 Thousand |
| Cash at end of period | 6.15 Million | 4.13 Million | 12.2 Million | 4.73 Million | 14.6 Million | 16.43 Million |
| Capital Expenditure | - | - | -1.82 Million | -3.83 Million | -4.17 Million | -7.17 Million |
| Effect of forex changes on cash | 1.5 Million | -448 Thousand | -55 Thousand | - | - | - |
| Net cash flow / Change in cash | 2.01 Million | -8.06 Million | 7.46 Million | -9.87 Million | -1.82 Million | 16.26 Million |
| Free Cash Flow | -41.34 Million | -32.95 Million | -31.98 Million | -26.83 Million | -30.73 Million | -20.53 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.76 Million | -7.9 Million | -44.61 Million | -13.74 Million | -12.51 Million | -8.69 Million |
| Depreciation & Amortization | 836 Thousand | 858 Thousand | 677 Thousand | 877 Thousand | 892 Thousand | 889 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -6.67 Million | -2.96 Million | -284 Thousand | -1.28 Million | 2.02 Million | 5.35 Million |
| Other non-cash items | 8.34 Million | 4.67 Million | 4.5 Million | 3.04 Million | -476 Thousand | 867 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 25.54 Million | 10.11 Million | 41.86 Million | 11.17 Million | 17.53 Million | -524 Thousand |
| Debt repayment | -34 Thousand | -34 Thousand | -1.26 Million | -27 Thousand | -2.39 Million | -524 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 25.57 Million | 10.14 Million | 43.12 Million | 11.2 Million | 19.92 Million | - |
| Other Financing Activities | 25.57 Million | 10.14 Million | 43.12 Million | 11.2 Million | 19.92 Million | -524 Thousand |
| Accounts receivables | -760 Thousand | -1.27 Million | 2.25 Million | 69 Thousand | 2.56 Million | -242 Thousand |
| Accounts payables | -6.18 Million | 2.43 Million | -1.08 Million | -2.69 Million | -1.89 Million | 5.8 Million |
| Inventory | 272 Thousand | -4.12 Million | -1.45 Million | 1.34 Million | -847 Thousand | -210 Thousand |
| Other working capital | -6.18 Million | 2.43 Million | -1.08 Million | -2.69 Million | 2.2 Million | 5.8 Million |
| Cash at beginning of period | 4.18 Million | 6.15 Million | 4.13 Million | 6.74 Million | 247 Thousand | 2.38 Million |
| Cash at end of period | 17.37 Million | 4.18 Million | 6.15 Million | 6.15 Million | 6.74 Million | 247 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | 247 Thousand | -2.06 Million | 1.5 Million | 2.39 Million | -974 Thousand | -35 Thousand |
| Net cash flow / Change in cash | 13.18 Million | -1.96 Million | 2.01 Million | -588 Thousand | 6.49 Million | -2.14 Million |
| Free Cash Flow | -12.6 Million | -10 Million | -41.34 Million | -14.15 Million | -10.06 Million | -1.58 Million |
300748
2764
LOGL
TIGER
CHMBBRW
NSHS